Does Aetna (CVS Health) Cover Retatrutide?

Why Aetna Does Not Currently Cover Retatrutide

Aetna (CVS Health) cannot add a drug to its formulary until the FDA grants approval. Retatrutide remains investigational. Eli Lilly's Phase 3 program is ongoing, and no New Drug Application (NDA) has been accepted by the FDA as of this writing.

The Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023; N=338) demonstrated that retatrutide at the highest dose (12 mg) produced a 24.2% mean reduction in body weight at 48 weeks, compared to 2.1% with placebo [1]. These results generated significant interest, but clinical trial performance alone does not trigger insurance coverage. The FDA must first review safety data, manufacturing quality, and labeling before any commercial launch can begin.

Patients enrolled in Eli Lilly's clinical trials may receive retatrutide at no cost through the study protocol. Outside of a trial, there is no legal pathway to obtain the drug in the United States. Any online source claiming to sell "retatrutide" before FDA approval is selling an unregulated compound that may contain incorrect doses, contaminants, or no active ingredient at all. The FDA has warned consumers about counterfeit weight-loss products repeatedly.

What Makes Retatrutide Different from Existing GLP-1 Drugs

Retatrutide is the first triple-hormone receptor agonist to reach late-stage clinical development for obesity. It activates three targets simultaneously: GLP-1, GIP, and glucagon receptors.

Semaglutide (Wegovy) targets GLP-1 alone. Tirzepatide (Zepbound) targets GLP-1 and GIP. Retatrutide adds glucagon receptor activation, which increases energy expenditure and promotes hepatic fat oxidation. This third mechanism is what separates it from every approved anti-obesity medication on the market today [1].

In the Phase 2 trial, participants receiving the 12 mg dose lost nearly a quarter of their body weight in under a year [1]. For context, the SURMOUNT-1 trial of tirzepatide (N=2,539) showed 22.5% mean weight loss at the highest dose over 72 weeks [2]. Retatrutide achieved comparable or greater weight loss in a shorter timeframe, though head-to-head comparisons between the two drugs have not been conducted.

The glucagon receptor component may also provide distinct benefits for metabolic-associated steatotic liver disease (MASLD). The Phase 2 data showed that 90% of participants with baseline liver fat above 10% achieved normalization of liver fat content (<5%) at the 12 mg dose [1]. No approved anti-obesity drug has demonstrated this degree of hepatic fat reduction.

How Aetna Handles Anti-Obesity Medications Right Now

Aetna's current coverage policies for weight-management drugs provide a reliable template for how the insurer will likely handle retatrutide once it reaches the market.

As of 2026, Aetna covers semaglutide (Wegovy) and tirzepatide (Zepbound) for chronic weight management under Clinical Policy Bulletin 0757, but only when members meet specific criteria. The standard requirements include a BMI of 30 kg/m² or greater (or BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), documented failure of lifestyle modification for at least 6 months, and completion of step therapy with at least one lower-cost agent [3].

Aetna places both Wegovy and Zepbound on specialty tiers within its CVS Caremark formulary, typically Tier 4 or Tier 5 depending on the specific plan. Member cost-sharing at these tiers ranges from 25% to 50% coinsurance, or fixed copays of $150 to $500 per fill. Some employer-sponsored plans exclude anti-obesity medications entirely, regardless of FDA approval status.

Dr. Caroline Apovian, a co-author of the Endocrine Society's 2015 obesity pharmacotherapy guidelines, has noted: "Insurance coverage for obesity medications has improved over the past decade, but prior authorization requirements remain the single biggest barrier to patient access" [4].

Expected Prior Authorization Criteria for Retatrutide on Aetna

Aetna will almost certainly require prior authorization for retatrutide. The insurer applies PA to every branded anti-obesity medication in its formulary. Based on existing patterns, the criteria will likely mirror or exceed what Aetna currently requires for Zepbound.

Expected requirements based on Aetna's existing anti-obesity PA framework:

Clinical eligibility. BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related comorbidity. The prescriber will need to document the member's height, weight, and comorbidity diagnosis codes.

Lifestyle modification documentation. Evidence of participation in a structured diet and exercise program for a minimum of 6 months. Some Aetna plans require documentation from a registered dietitian or a formal weight-management program.

Step therapy completion. Failure of, intolerance to, or contraindication to at least one preferred anti-obesity agent. Aetna currently requires trial of a preferred GLP-1 before approving a non-preferred option. If retatrutide launches at a premium to Zepbound, Aetna may require documented trial of tirzepatide first.

Prescriber specialty. Some Aetna plans restrict anti-obesity medication prescribing to endocrinologists, obesity medicine specialists, or primary care physicians with documented obesity management training.

Reauthorization intervals. Aetna typically approves anti-obesity medications for 6 to 12 months, then requires reauthorization with documentation of at least 5% weight loss from baseline. Members who do not meet this threshold may lose coverage.

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm recommends that insurers approve anti-obesity medications based on clinical indication rather than step therapy, stating: "Step therapy requirements for obesity pharmacotherapy are not evidence-based and delay effective treatment" [5]. Aetna has not adopted this recommendation.

Step Therapy: What Aetna Will Likely Require Before Retatrutide

Step therapy means you must try and fail a cheaper drug before Aetna will approve the one your doctor originally prescribed. This is standard practice for anti-obesity medications across all major commercial insurers.

Aetna's current step therapy ladder for weight-management drugs generally follows this order: generic orlistat or phentermine first, then a preferred GLP-1 agonist (currently Wegovy or Zepbound, depending on the plan year), then non-preferred agents. Retatrutide, as a novel triple agonist with no generic equivalent, will almost certainly sit at the top of this ladder.

A "trial and failure" typically means the member took the step-therapy drug at an adequate dose for 90 days without achieving the target weight-loss threshold (usually 5% of body weight), or experienced a documented adverse effect that prevented continuation. Your prescriber must include this documentation in the PA request.

There is an exception pathway. If your doctor can document a clinical contraindication to the step-therapy drug (for example, a history of medullary thyroid carcinoma contraindicating all GLP-1 agonists, or pancreatitis on tirzepatide), Aetna may waive the step requirement. The contraindication must be specific and supported by chart notes.

Step therapy adds 3 to 6 months to the timeline before a member can access a non-preferred agent. For patients whose BMI exceeds 40 kg/m², this delay carries real clinical consequences. The Endocrine Society's 2024 position statement explicitly calls for elimination of step therapy for patients with severe obesity (BMI ≥40 kg/m²) [6].

How to Appeal an Aetna Denial of Retatrutide

If Aetna denies your prior authorization request for retatrutide after the drug reaches the market, you have the right to appeal. The process follows a two-stage structure mandated by federal and state insurance regulations.

First-level internal appeal. You or your prescriber must file a written appeal within 180 days of the denial. Include the original PA request, the denial letter, updated clinical documentation (BMI, comorbidities, step-therapy failures), and a letter of medical necessity from the prescribing physician. Aetna must respond within 30 days for a standard appeal or 72 hours for an expedited (urgent) appeal. The review is conducted by a physician who was not involved in the original denial.

External review. If the internal appeal is denied, you can request an independent external review through your state's insurance department. An external reviewer not affiliated with Aetna will evaluate the clinical evidence. The Patient Protection and Affordable Care Act guarantees this right for all members of non-grandfathered health plans [7].

Practical tips that increase approval odds: submit peer-reviewed literature supporting the drug's efficacy for your specific clinical scenario, include the Jastreboff et al. Phase 2 data [1], document every prior medication trial with dates, doses, and outcomes, and have your physician cite relevant guideline recommendations from the AACE or Endocrine Society.

Appeals succeed more often than most patients expect. A 2023 KFF analysis found that among ACA marketplace plans, roughly 40% of internal appeals resulted in overturned denials [8]. The rate for anti-obesity medications specifically is not published, but anecdotal reporting from obesity medicine practices suggests comparable success rates when clinical documentation is thorough.

Manufacturer Savings Programs and Cost Alternatives

Eli Lilly has not announced a patient savings program for retatrutide because the drug is not yet approved or priced. Once retatrutide launches, Lilly is expected to offer a manufacturer savings card based on its existing pattern with tirzepatide (Zepbound).

For reference, Lilly's Zepbound savings card currently reduces commercially insured patients' out-of-pocket cost to as low as $25 per month for qualifying members. Savings cards typically cannot be combined with Medicare, Medicaid, Tricare, or other government-funded insurance. Aetna commercial plans generally permit use of manufacturer copay cards, but the savings card amount does not count toward the member's deductible or out-of-pocket maximum.

If Aetna denies coverage entirely and no savings card is available, patients will face the full cash price. Retatrutide's list price has not been set. Analyst estimates based on the competitive GLP-1 market suggest pricing between $900 and $1,300 per month, comparable to Zepbound's current list price of $1,059.87 per month. Without insurance, specialty pharmacies and compounding are the typical alternative pathways, though compounded retatrutide will not be available unless the drug faces a documented shortage after approval.

What Happens When Retatrutide Gets FDA Approval

The timeline from FDA approval to Aetna formulary inclusion is not instantaneous. Several steps must occur in sequence.

First, the FDA grants approval and publishes the prescribing label. Second, Eli Lilly sets the wholesale acquisition cost (WAC) and launches commercially. Third, CVS Caremark (Aetna's pharmacy benefit manager) evaluates the drug for formulary placement during its next Pharmacy and Therapeutics Committee review cycle. These cycles occur quarterly. Fourth, Aetna publishes a clinical policy bulletin specific to retatrutide, detailing PA criteria, step therapy requirements, and covered indications.

This process typically takes 3 to 6 months from FDA approval to plan-level coverage. During the gap period, prescribers can submit PA requests, but they are likely to be denied as "not yet reviewed" rather than "medically unnecessary." Some Aetna plans may grant coverage earlier through a medical exception process if the prescriber provides compelling clinical justification.

The FDA's drug approval process page outlines the standard review timeline: 10 months for a standard review or 6 months for a priority review from NDA acceptance [9]. Eli Lilly has not disclosed whether it will seek priority review for the obesity indication.

Retatrutide for Type 2 Diabetes vs. Weight Loss: Coverage Differences on Aetna

Eli Lilly is developing retatrutide for both obesity and type 2 diabetes. The indication on the FDA label will directly affect how Aetna covers the drug.

Anti-obesity medications and diabetes medications follow different coverage pathways on Aetna. Diabetes drugs are covered under the pharmacy benefit with generally lower cost-sharing and fewer PA restrictions. Anti-obesity medications face higher formulary tiers, stricter PA criteria, and the possibility of complete exclusion on some employer-sponsored plans.

If the FDA approves retatrutide for type 2 diabetes first (or simultaneously with the obesity indication), Aetna members with a diabetes diagnosis may gain access sooner and at lower cost. This pattern played out with tirzepatide: Mounjaro (the diabetes brand) received FDA approval in May 2022, while Zepbound (the obesity brand) was not approved until November 2023. During that 18-month gap, some prescribers used Mounjaro off-label for weight loss, though Aetna does not cover off-label use of diabetes medications for obesity.

The distinction matters for patients with both conditions. A member with a BMI of 35 kg/m² and an A1c of 7.2% might qualify for retatrutide under the diabetes indication (if approved), bypassing the more restrictive anti-obesity PA pathway entirely.